Achieving precise, safe, and scalable extrahepatic delivery remains one of the most complex challenges in lipid nanoparticle (LNP) development.
This page outlines the six most critical bottlenecks holding the field back - and highlights the expert-led sessions designed to address them.
Choosing Between Active vs Passive Targeting
Why this bottleneck matters:
Choosing between passive and active targeting is one of the most decisive early challenges in LNP development. Passive strategies offer scalability but limited precision, while active targeting improves selectivity at the cost of manufacturing and analytical complexity.
Key Session Addressing This Bottleneck:
- Workshop A: Debating Active & Passive Targeting Strategies to Identify the Best Approach for Achieving Scalable, Specific, & Selective Nanoparticles
Speakers:
- Pintu Kanjilal, Scientist, LNP Discovery, Strand Therapeutics
- Justin Fang, Senior Scientist, Formulations, Mote Therapeutics
Targeted LNP Analytics & Scalability
Why this bottleneck matters:
Choosing between passive and active targeting is one of the most decisive early challenges in LNP development. Passive strategies offer scalability but limited precision, while active targeting improves selectivity at the cost of manufacturing and analytical complexity.
Key Session Addressing This Bottleneck:
- Workshop B: Designing Robust Analytics & Scalable Processes for Targeted LNPs to Achieve Clinical Readiness
Speakers:
- Ketaki Deshmukh, Senior Scientist, Novo Nordisk
- Sanjib Saha, Senior Scientist, Advanced Drug Delivery, AstraZeneca
Achieving Selective Delivery Beyond the Liver
Why this bottleneck matters:
Overcoming innate liver tropism is essential to unlock extrahepatic therapies targeting muscles, immune cells, lungs, and the CNS.
Key Session Addressing This Bottleneck:
- Engineering Single-Component Homogeneous Amphiphilic Routed Particles (SHARP) to Program Organ Tropism
Speaker: Cangjie Yang, Associate Director, Zipcode Bio
- Enhancing Immune Modulation through Rational Design of LNPs
Speaker: Neha Kapate, Senior Scientist I, AbbVie
- A T Cell Selective LNP to Deliver STING Agonists
Speaker: Emily Gosselin, Senior Scientist, Corner Therapeutics
- Panel Discussion: Exploring the Future of Extrahepatic LNPs
Safety & Toxicity
Why this bottleneck matters:
Immunogenicity, dose limitation, and PEG-related toxicity remain major barriers to repeat dosing and chronic therapeutic use.
Key Session Addressing This Bottleneck:
- Evaluating PEG-Alternative LNPs for Extrahepatic Delivery in In Vivo Cell Reprogramming
Speaker: Hongjing Xia, Principal Scientist, Novartis
- Roundtable: Minimizing Immunogenicity While Maximizing Efficacy in Targeted LNPs
New & Innovative Delivery Vehicle Designs
Why this bottleneck matters:
Conventional LNPs may not be sufficient for next-generation therapeutic needs, driving exploration of peptides, polymers, and hybrid architectures.
Key Session Addressing This Bottleneck:
- Next-Gen Stealth Fusion LNP with Endosomal Bypass Core
Speaker: Raj Reddy, CEO, Canary Cure Therapeutics
- Payload Delivery Tool Kit: Lipids vs Polymers
Speaker: Kanika Suri, Scientist, Takeda Pharmaceuticals
- Overcoming Hepatic Accumulation Using a Redosable Peptide-Based Nanoparticle Platform
Speaker: Gilles Divita, CEO & CSO, AANASTRA
- Enhancing Cytosolic Delivery Using Peptides
Speaker: Soultan Al-Halifa, Director R&D, Feldan Therapeutics
High-Throughput LNP Screening
Why this bottleneck matters:
High-throughput screening is critical to understand how subtle formulation changes impact efficacy, safety, and organ selectivity.
Key Session Addressing This Bottleneck:
- Deliveromics & GT AI for Cell-Type Specific LNP Design
Speaker: Chi Zhang, Co-Founder & CSO, GT Biosciences
- High-Throughput Screening of Charge-Switchable Lipids
Speaker: Atip Lawanprasert, Postdoctoral Fellow, UC Berkeley
- Improved High-Throughput Screening for Extrahepatic LNP Delivery
Speaker: Lihi Zaks, Research Associate, Novo Nordisk
- Panel Discussion: Advanced Screening Platforms for Extrahepatic LNP Discovery
Ready to overcome these bottlenecks?
Download the full brochure to explore detailed case studies, expert presentations, and strategic insights.